Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccinesSASADA, Tetsuro; KOMATSU, Nobukazu; SUEKANE, Shigetaka et al.European journal of cancer (1990). 2010, Vol 46, Num 9, pp 1514-1519, issn 0959-8049, 6 p.Article

Evaluation of a new oil adjuvant for use in peptide-based cancer vaccinationISEKI, Kanako; MATSUNAGA, Hiromi; KOMATSU, Nobukazu et al.Cancer science. 2010, Vol 101, Num 10, pp 2110-2114, issn 1347-9032, 5 p.Article

A randomized clinical trial of suspension technique for improving early recovery of urinary continence after radical retropubic prostatectomyNOGUCHI, Masanori; KAKUMA, Tatsuyuki; SUEKANE, Shigetaka et al.BJU international (Papier). 2008, Vol 102, Num 8, pp 958-963, issn 1464-4096, 6 p.Article

Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients : An analysis of prognostic factors in the treatmentNOGUCHI, Masanori; MINE, Takashi; YAMADA, Akira et al.Oncology research. 2007, Vol 16, Num 7, pp 341-349, issn 0965-0407, 9 p.Article

HLA-G as a target molecule in specific immunotherapy against renal cell carcinomaKOMOHARA, Yoshihiro; HARADA, Mamoru; ISHIHARA, Yuki et al.Oncology reports. 2007, Vol 18, Num 6, pp 1463-1468, issn 1021-335X, 6 p.Article

Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancerNOGUCHI, Masanori; ITOH, Kyogo; SUEKANE, Shigetaka et al.The Prostate. 2004, Vol 60, Num 1, pp 32-45, issn 0270-4137, 14 p.Article

Phase II Study of Personalized Peptide Vaccination for Castration-Resistant Prostate Cancer Patients Who Failed in Docetaxel-Based ChemotherapyNOGUCHI, Masanori; MORIYA, Fukuko; SUEKANE, Shigetaka et al.The Prostate. 2012, Vol 72, Num 8, pp 834-845, issn 0270-4137, 12 p.Article

Gene Expression Profiles in Peripheral Blood as a Biomarker in Cancer Patients Receiving Peptide VaccinationKOMATSU, Nobukazu; MATSUEDA, Satoko; MATSUOKA, Kei et al.Cancer. 2012, Vol 118, Num 12, pp 3208-3221, issn 0008-543X, 14 p.Article

Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancerNOGUCHI, Masanori; ITOH, Kyogo; SUEKANE, Shigetaka et al.Cancer science. 2004, Vol 95, Num 1, pp 77-84, issn 1347-9032, 8 p.Article

Identification of target antigens in specific immunotherapy for renal cell carcinomaKOMOHARA, Yoshihiro; HARADA, Mamoru; ARIMA, Yoshimi et al.The Journal of urology. 2007, Vol 177, Num 3, pp 1157-1162, issn 0022-5347, 6 p.Article

Anti-cancer vaccine candidates in specific immunotherapy for bladder carcinomaKOMOHARA, Yoshihiro; HARADA, Mamoru; ARIMA, Yoshimi et al.International journal of oncology. 2006, Vol 29, Num 6, pp 1555-1560, issn 1019-6439, 6 p.Article

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24⁺ HRPC patientsNOGUCHI, Masanori; ITOH, Kyogo; YAO, Akihisa et al.The Prostate. 2005, Vol 63, Num 1, pp 1-12, issn 0270-4137, 12 p.Article

A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancerNOGUCHI, Masanori; KAKUMA, Tatsuyuki; SHICHIJO, Shigeki et al.Cancer immunology and immunotherapy. 2010, Vol 59, Num 7, pp 1001-1009, issn 0340-7004, 9 p.Article

Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patientsSUEKANE, Shigetaka; NISHITANI, Masaaki; KANAYAMA, Hiroomi et al.Cancer science. 2007, Vol 98, Num 12, pp 1965-1968, issn 1347-9032, 4 p.Article